MALVERN, Pa., January 28, 2013 – TetraLogic Pharmaceuticals today announced that the Japan
Patent Office (JPO) issued a Decision to Grant the company a patent that claims birinapant, a Smac
mimetic currently in Phase 2 clinical studies for the treatment of various cancers. The allowed Japanese
patent application, JP 2007-557249, has claims directed to the class of Smac mimetics that encompasses
birinapant as a new chemical entity (NCE) and to drug products comprising birinapant and structurally
related Smac mimetics.
A Decision to Grant is issued after the JPO makes a determination that a patent can be granted from an
application. The issued patent would have a term that expires no earlier than in 2026.
This application is part of an expanding international patent portfolio for TetraLogic with Japan being the
ninth country to acknowledge the patentability of the company’s Smac mimetics. Others include the
United States, People's Republic of China, Eurasian Patent Office (which incudes Russia), Australia,
India, Mexico, Singapore and South Africa. Additional counterpart patent applications are pending
examination in Europe, Brazil, Canada, Israel, and Korea.
Read more: http://files.shareholder.com/downloads/AMDA-2C8MW4/2989657472x0x707411/04e4f92e-1b68-43e7-840e-d6480321c1cf/707411.pdf
Type 1 and type 2 diabetes results when beta cells in the pancreas fail to produce enough insulin, the hormone that regulates blood sugar. One approach to treating diabetes is to stimulate regeneration of new beta cells.